Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

BACKGROUND: Blinatumomab is a CD19 BiTE (bispecific T‐cell engager) immuno‐oncology therapy that mediates the lysis of cells expressing CD19. METHODS: A pooled analysis of long‐term follow‐up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chrom...

Descripción completa

Detalles Bibliográficos
Autores principales: Topp, Max S., Gökbuget, Nicola, Zugmaier, Gerhard, Stein, Anthony S., Dombret, Hervé, Chen, Yuqi, Ribera, Josep‐Maria, Bargou, Ralf C., Horst, Heinz‐August, Kantarjian, Hagop M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894150/
https://www.ncbi.nlm.nih.gov/pubmed/33141929
http://dx.doi.org/10.1002/cncr.33298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894150/
https://www.ncbi.nlm.nih.gov/pubmed/33141929
http://dx.doi.org/10.1002/cncr.33298

Ejemplares similares